ZIC2

Across TCGA pan-cancer cohorts, ZIC2 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ZIC2 data layer compared with 27 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher ZIC2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ZIC2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LUSC, COAD, and UCEC are the cancer types where ZIC2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	III,IV	0.147	0.664	.028	15	view →
COAD	OS	Median	All	0.111	0.871	<.001	12	view →
UCEC	DFS	Median	II,III,IV	1.000	0.443	.030	10	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

ZIC2–LUSC (OS)

Open the LUSC breakdown →